Amgen (NASDAQ:AMGN – Free Report) had its price objective upped by UBS Group from $284.00 to $307.00 in a research report report published on Friday morning, Benzinga reports. UBS Group currently has a neutral rating on the medical research company’s stock. A number of other analysts also recently issued reports on the stock. Truist Financial […]
Axxcess Wealth Management LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 11.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,362 shares of the medical research company’s stock after purchasing an additional 1,518 shares during the […]
Barclays upgraded shares of Amgen (NASDAQ:AMGN – Free Report) from an underweight rating to an equal weight rating in a research report report published on Friday, MarketBeat reports. The firm currently has $300.00 price objective on the medical research company’s stock, up from their previous price objective of $230.00. Several other analysts have also issued […]
Amgen (NASDAQ:AMGN – Free Report) had its price target boosted by UBS Group from $284.00 to $307.00 in a report released on Friday, Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock. AMGN has been the subject of a number of other reports. William Blair upgraded Amgen from a […]
Amgen (NASDAQ:AMGN – Free Report) had its target price reduced by Royal Bank of Canada from $332.00 to $328.00 in a report issued on Friday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the medical research company’s stock. Several other research analysts also recently commented on AMGN. SVB Leerink downgraded […]